Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the IASLC
There have been major advancements in therapies and diagnostics for advanced stage non-small cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in the therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.
The IASLC first published a recommendations statement on liquid biopsy in 2018, but the field has grown significantly since and there have been changes in the therapeutic decision making algorithm for advanced NSCLC and thus a updated recommendations was just recently published, July 2021, in the Journal of Thoracic Oncology.
This webinar will feature interactive case-based panel discussions to review the state of the field for liquid biopsy in NSCLC and discuss the standard of care recommendations for a global audience that were proposed in the recently published IASLC consensus statement on liquid biopsy.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance